Cognitive Deficits Found in a Pro-inflammatory State are Independent of ERK1/2 Signaling in the Murine Brain Hippocampus Treated with Shiga Toxin 2 from Enterohemorrhagic Escherichia coli

Cell Mol Neurobiol. 2023 Jul;43(5):2203-2217. doi: 10.1007/s10571-022-01298-1. Epub 2022 Oct 13.

Abstract

Shiga toxin 2 (Stx2) from enterohemorrhagic Escherichia coli (EHEC) produces hemorrhagic colitis, hemolytic uremic syndrome (HUS), and acute encephalopathy. The mortality rate in HUS increases significantly when the central nervous system (CNS) is involved. Besides, EHEC also releases lipopolysaccharide (LPS). Many reports have described cognitive dysfunctions in HUS patients, the hippocampus being one of the brain areas targeted by EHEC infection. In this context, a translational murine model of encephalopathy was employed to establish the deleterious effects of Stx2 and the contribution of LPS in the hippocampus. The purpose of this work is to elucidate the signaling pathways that may activate the inflammatory processes triggered by Stx2, which produces cognitive alterations at the level of the hippocampus. Results demonstrate that Stx2 produced depression-like behavior, pro-inflammatory cytokine release, and NF-kB activation independent of the ERK1/2 signaling pathway, while co-administration of Stx2 and LPS reduced memory index. On the other hand, LPS activated NF-kB dependent on ERK1/2 signaling pathway. Cotreatment of Stx2 with LPS aggravated the pathologic state, while dexamethasone treatment succeeded in preventing behavioral alterations. Our present work suggests that the use of drugs such as corticosteroids or NF-kB signaling inhibitors may serve as neuroprotectors from EHEC infection.

Keywords: Cell signaling; Cognitive deficits; Dexamethasone; Hippocampus; Lipopolysaccharides; Microglia; Shiga toxin.

MeSH terms

  • Animals
  • Brain / pathology
  • Brain Diseases*
  • Cognition
  • Cognitive Dysfunction*
  • Enterohemorrhagic Escherichia coli*
  • Escherichia coli Infections* / complications
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Infections* / pathology
  • Hemolytic-Uremic Syndrome*
  • Hippocampus / pathology
  • Humans
  • Lipopolysaccharides / pharmacology
  • MAP Kinase Signaling System
  • Mice
  • NF-kappa B
  • Shiga Toxin 2 / toxicity

Substances

  • Shiga Toxin 2
  • Lipopolysaccharides
  • NF-kappa B